Flex Pharma Announces FLX-787 as Clinical Drug Candidate
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Flex Pharma (FLKS) Selects FLX-787 as Clinical Drug Candidate
November 10, 2015 4:24 PM ESTFlex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions, announced today at its Investor Day in New York City that the Company has selected FLX-787 as its clinical candidate for studies outside the United States. FLX-787 is a purified, GMP-synthesized single agent consisting of one highly selective and specific transient receptor potential (TRP) ion channel agonist.
After testing the most potent TRPA1 and TRPV1 agonists and demonstrating enhanced efficacy... More
